Drug firm Zydus Healthcare on Sunday said it has launched generic anti-diabetic Dapagliflozin tablets across the country under the brand name 'Dapaglyn' at highly affordable price to increase patient access.
The company has launched its Dapagliflozin tablets in the strengths of 10 mg and 5 mg priced at Rs 17 and Rs 14, respectively, in India upon patent expiry of the product,Zydus Healthcare said in a statement.
"In keeping with its efforts to make therapies accessible and affordable to patients, the drug will be highly economical, priced at 1/3rd the cost than currently available Dapagliflozin brands in India," it added.
The once-daily tablets are indicated as an adjunct to diet and exercise, and aim to improve glycemic control in adults with Type 2 diabetes mellitus, Zydus Healthcare said.
Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors,it added.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.